ReutersChina's CanSino Biologics Inc said on Sunday that its recently developed Covid-19 vaccine has been approved by the country's drug regulator for emergency use as a booster, potentially benefiting its business.
The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.
"The approval will have a positive impact on the company's performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.
The company cautioned, however, that it will face fierce competition from other vaccines in China that have also obtained government approval or are in clinical trials.
China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's Covid-19 vaccine as a booster, Livzon said on Friday, one of just two new products against the disease the country had cleared in more than a year.
The inhaled version of Cansino's adenovirus-vectored Covid-19 vaccine has obtained the green light from the National Medical Products Administration, the company said in a filing on Sunday.
"The approval will have a positive impact on the company's performance if the vaccine is subsequently purchased and used by relevant government agencies," CanSino said.
The company cautioned, however, that it will face fierce competition from other vaccines in China that have also obtained government approval or are in clinical trials.
China granted emergency use authorisation to Livzon Pharmaceutical Group Inc's Covid-19 vaccine as a booster, Livzon said on Friday, one of just two new products against the disease the country had cleared in more than a year.
Experience Your Economic Times Newspaper, The Digital Way!
Read More News on
(Catch all the Business News, Breaking News Events and Latest News Updates on The Economic Times.)
...moreDownload The Economic Times News App to get Daily Market Updates & Live Business News.
